These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

891 related items for PubMed ID: 19124807

  • 1. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG, HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
    J Clin Oncol; 2009 Feb 10; 27(5):805-11. PubMed ID: 19124807
    [Abstract] [Full Text] [Related]

  • 2. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

  • 3. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M, Intergruppo Italiano Linfomi.
    J Clin Oncol; 2005 Dec 20; 23(36):9198-207. PubMed ID: 16172458
    [Abstract] [Full Text] [Related]

  • 4. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M.
    J Clin Oncol; 2016 Apr 10; 34(11):1175-81. PubMed ID: 26712220
    [Abstract] [Full Text] [Related]

  • 5. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7555-64. PubMed ID: 16234521
    [Abstract] [Full Text] [Related]

  • 6. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M.
    J Clin Oncol; 2009 Sep 20; 27(27):4548-54. PubMed ID: 19704068
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
    Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M.
    J Clin Oncol; 2011 Nov 10; 29(32):4227-33. PubMed ID: 21990405
    [Abstract] [Full Text] [Related]

  • 8. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M, German Hodgkin's Lymphoma Study Group.
    N Engl J Med; 2003 Jun 12; 348(24):2386-95. PubMed ID: 12802024
    [Abstract] [Full Text] [Related]

  • 9. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Diehl V, Fuchs M, GHSG.
    Transfus Apher Sci; 2007 Aug 12; 37(1):37-41. PubMed ID: 17714996
    [Abstract] [Full Text] [Related]

  • 10. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 11. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
    J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
    [Abstract] [Full Text] [Related]

  • 12. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
    Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.
    J Clin Oncol; 2011 Nov 10; 29(32):4234-42. PubMed ID: 21990399
    [Abstract] [Full Text] [Related]

  • 13. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B.
    Lancet Haematol; 2021 Apr 10; 8(4):e278-e288. PubMed ID: 33770483
    [Abstract] [Full Text] [Related]

  • 14. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V.
    J Clin Oncol; 2007 Aug 10; 25(23):3495-502. PubMed ID: 17606976
    [Abstract] [Full Text] [Related]

  • 15. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M.
    J Clin Oncol; 1998 Dec 10; 16(12):3810-21. PubMed ID: 9850026
    [Abstract] [Full Text] [Related]

  • 16. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?
    Diehl V, Behringer K.
    Cancer Invest; 2006 Dec 10; 24(4):461-5. PubMed ID: 16777701
    [Abstract] [Full Text] [Related]

  • 17. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?
    Diehl V, Behringer K.
    Cancer Invest; 2006 Nov 10; 24(7):713-7. PubMed ID: 17118782
    [Abstract] [Full Text] [Related]

  • 18. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY.
    Ai Zheng; 2006 Aug 10; 25(8):1013-8. PubMed ID: 16965685
    [Abstract] [Full Text] [Related]

  • 19. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
    Josting A, Nogová L, Franklin J, Glossmann JP, Eich HT, Sieber M, Schober T, Boettcher HD, Schulz U, Müller RP, Diehl V, Engert A.
    J Clin Oncol; 2005 Mar 01; 23(7):1522-9. PubMed ID: 15632410
    [Abstract] [Full Text] [Related]

  • 20. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N, Berthou C, Desablens B, de Guibert S, Delwail V, Moles MP, Quittet P, Jais JP, Colonna P, Andrieu JM, Groupe Ouest-Est d'Etude des Leucémies et Autres Maladies du Sang.
    Cancer; 2008 Dec 15; 113(12):3323-30. PubMed ID: 18988286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.